164 related articles for article (PubMed ID: 15802020)
1. Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.
Ulivi P; Zoli W; Fabbri F; Brigliadori G; Ricotti L; Tesei A; Rosetti M; De Cesare M; Beretta GL; Corna E; Supino R; Zunino F
Neoplasia; 2005 Feb; 7(2):152-61. PubMed ID: 15802020
[TBL] [Abstract][Full Text] [Related]
2. A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo.
Zou J; Li S; Chen Z; Lu Z; Gao J; Zou J; Lin X; Li Y; Zhang C; Shen L
Cell Death Dis; 2018 May; 9(6):661. PubMed ID: 29855512
[TBL] [Abstract][Full Text] [Related]
3. Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
Gounder MK; Nazar AS; Saleem A; Pungaliya P; Kulkarni D; Versace R; Rubin EH
Invest New Drugs; 2008 Jun; 26(3):205-13. PubMed ID: 17943230
[TBL] [Abstract][Full Text] [Related]
4. Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect.
Prada CF; Alvarez-Velilla R; Balaña-Fouce R; Prieto C; Calvo-Álvarez E; Escudero-Martínez JM; Requena JM; Ordóñez C; Desideri A; Pérez-Pertejo Y; Reguera RM
Biochem Pharmacol; 2013 May; 85(10):1433-40. PubMed ID: 23466420
[TBL] [Abstract][Full Text] [Related]
5. The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
Di Francesco AM; Riccardi A; Barone G; Rutella S; Meco D; Frapolli R; Zucchetti M; D'Incalci M; Pisano C; Carminati P; Riccardi R
Biochem Pharmacol; 2005 Oct; 70(8):1125-36. PubMed ID: 16139802
[TBL] [Abstract][Full Text] [Related]
6. Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.
Zuco V; Supino R; De Cesare M; Carenini N; Perego P; Gatti L; Pratesi G; Pisano C; Martinelli R; Bucci F; Zanier R; Carminati P; Zunino F
Biochem Pharmacol; 2003 Apr; 65(8):1281-94. PubMed ID: 12694869
[TBL] [Abstract][Full Text] [Related]
7. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
8. Subcellular localization of the camptothecin analogues, topotecan and gimatecan.
Croce AC; Bottiroli G; Supino R; Favini E; Zuco V; Zunino F
Biochem Pharmacol; 2004 Mar; 67(6):1035-45. PubMed ID: 15006540
[TBL] [Abstract][Full Text] [Related]
9. Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft.
Petrangolini G; Tortoreto M; Perego P; Carenini N; De Cesare M; Balsari A; Zunino F; Pratesi G
Cancer Biol Ther; 2008 Apr; 7(4):596-601. PubMed ID: 18364568
[TBL] [Abstract][Full Text] [Related]
10. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
Van Hattum AH; Schlüper HM; Hausheer FH; Pinedo HM; Boven E
Int J Cancer; 2002 Jul; 100(1):22-9. PubMed ID: 12115582
[TBL] [Abstract][Full Text] [Related]
11. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Emerson DL; Besterman JM; Brown HR; Evans MG; Leitner PP; Luzzio MJ; Shaffer JE; Sternbach DD; Uehling D; Vuong A
Cancer Res; 1995 Feb; 55(3):603-9. PubMed ID: 7834631
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Sorensen M; Sehested M; Jensen PB
Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.
Zuco V; Supino R; Favini E; Tortoreto M; Cincinelli R; Croce AC; Bucci F; Pisano C; Zunino F
Biochem Pharmacol; 2010 Feb; 79(4):535-41. PubMed ID: 19765546
[TBL] [Abstract][Full Text] [Related]
14. DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
Vassal G; Pondarré C; Cappelli C; Terrier-Lacombe MJ; Boland I; Morizet J; Bénard J; Vénuat AM; Ardouin P; Hartmann O; Gouyette A
Eur J Cancer; 1997 Oct; 33(12):2011-5. PubMed ID: 9516844
[TBL] [Abstract][Full Text] [Related]
15. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
[TBL] [Abstract][Full Text] [Related]
17. Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways.
Chen Z; Liu Z; Huang W; Li Z; Zou J; Wang J; Lin X; Li B; Chen D; Hu Y; Ji J; Gao J; Shen L
J Transl Med; 2017 Dec; 15(1):253. PubMed ID: 29237470
[TBL] [Abstract][Full Text] [Related]
18. Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.
Huang M; Gao H; Chen Y; Zhu H; Cai Y; Zhang X; Miao Z; Jiang H; Zhang J; Shen H; Lin L; Lu W; Ding J
Clin Cancer Res; 2007 Feb; 13(4):1298-307. PubMed ID: 17287296
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.
Petrangolini G; Pratesi G; De Cesare M; Supino R; Pisano C; Marcellini M; Giordano V; Laccabue D; Lanzi C; Zunino F
Mol Cancer Res; 2003 Oct; 1(12):863-70. PubMed ID: 14573787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
